BriaCell Therapeutics (TSE:BCT) Stock Price Up 2.8% – Here’s What Happened

BriaCell Therapeutics Corp. (TSE:BCT)’s stock price was up 2.8% during mid-day trading on Monday . The stock traded as high as C$5.92 and last traded at C$5.86. Approximately 10,031 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 30,866 shares. The stock had previously closed at C$5.70.

BriaCell Therapeutics Stock Down 0.7%

The business has a fifty day moving average of C$5.72 and a 200 day moving average of C$11.02. The firm has a market cap of C$40.46 million, a P/E ratio of -0.39 and a beta of 2.37.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.